For each citation that was shared on social media (LinkedIn, Facebook, or Twitter) with the “@GenScript” tag, the author will be rewarded with a $10 Amazon gift card or 2,000 GS points.

GPR183 potentiates CAR-T cell infiltration and antitumor immunity through a positive feedback loop involving the oxysterol 7α,25-OHC

Molecular cancer. 2026-03; 
Rui Guo, Chang Guo, Sen Qin, Zhiwen Lin, Jinlian Tong, Yiran Wang, Zixuan Zhao, Wen Zuo, Qing Gao, Qin Tan, Jie Ma
Products/Services Used Details Operation
Synthetic Guide RNA Three specific sgRNAs targeting the GPR183 gene were designed and synthesized by GenScript Biotechnology Co., Ltd. (China). For use, the three sgRNAs were mixed in equimolar amounts and incubated with Cas9 protein (GenScript, China) at an optimized ratio (100 pmol sgRNA+5 µg Cas9 protein) to form a ribonucleoprotein (RNP) complex. For each target gene (CH25H and CYP7B1), three siRNA sequences were designed and synthesized by GenScript Biotechnology Co., Ltd. (China). Get A Quote
Custom DNA/RNA Oligos Get A Quote

Abstract

Background: Insufficient T cell infiltration into solid tumors represents a major barrier to effective immunotherapy, particularly in the context of CAR-T therapy. Identifying key molecules capable of promoting T cell migration to tumor sites is therefore critical. GPR183 (EBI2), a receptor for oxidized sterols, has not yet been fully characterized in terms of its role in antitumor T cell immunity or its potential for application in CAR-T cell engineering. Methods: Public single-cell transcriptomic data from breast cancer and ovarian cancer were analyzed to identify distinct expression patterns of GPR183 across T cell subsets, which were validated using flow cytometry. Functional assays, including in vitro T... More

Keywords

CAR-T therapy; GPR183; Positive feedback loop; Solid tumor treatment; T cell migration.